# Vericel Corp: overview

VCEL · Nasdaq · CIK 887359 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vcel.md) · [Financials](/companies/vcel/financials.md) · [Filings](/companies/vcel/filings.md) · [Insiders](/companies/vcel/insiders.md)

Latest reported revenue: [$77.5m](/filings/0001628280-26-050836.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-050836).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [57.9](/filings/0001628280-25-049902.md) | [75.4 d](/filings/0001628280-26-012013.md) | [52.6](/filings/0001628280-26-031742.md) | [63.2](/filings/0001628280-26-050836.md) | [67.5](/filings/0001628280-25-049902.md) | [92.9 d](/filings/0001628280-26-012013.md) | [68.4](/filings/0001628280-26-031742.md) | [77.5](/filings/0001628280-26-050836.md) |
| Gross margin | % | [71.9%](/filings/0001628280-25-049902.md) | [77.6% d](/filings/0001628280-26-012013.md) | [69.0%](/filings/0001628280-26-031742.md) | [73.7%](/filings/0001628280-26-050836.md) | [73.5%](/filings/0001628280-25-049902.md) | [78.7% d](/filings/0001628280-26-012013.md) | [72.0%](/filings/0001628280-26-031742.md) | [72.8%](/filings/0001628280-26-050836.md) |
| Operating margin | % | [(4.3%)](/filings/0001628280-25-049902.md) | [24.5% d](/filings/0001628280-26-012013.md) | [(24.3%)](/filings/0001628280-26-031742.md) | [(3.2%)](/filings/0001628280-26-050836.md) | [5.1%](/filings/0001628280-25-049902.md) | [24.1% d](/filings/0001628280-26-012013.md) | [(11.8%)](/filings/0001628280-26-031742.md) | [0.6%](/filings/0001628280-26-050836.md) |
| Net margin | % | [(1.6%)](/filings/0001628280-25-049902.md) | [26.3% d](/filings/0001628280-26-012013.md) | [(21.4%)](/filings/0001628280-26-050836.md) | [(0.9%)](/filings/0001628280-26-050836.md) | [7.5%](/filings/0001628280-25-049902.md) | [25.0% d](/filings/0001628280-26-012013.md) | [(9.2%)](/filings/0001628280-26-050836.md) | [2.8%](/filings/0001628280-26-050836.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0001628280-25-049902.md) | not reported | [(0.23)](/filings/0001628280-26-031742.md) | [(0.01)](/filings/0001628280-26-050836.md) | [0.10](/filings/0001628280-25-049902.md) | not reported | [(0.12)](/filings/0001628280-26-031742.md) | [0.04](/filings/0001628280-26-050836.md) |
| Free cash flow | $m | [(9.2) d](/filings/0001628280-25-049902.md) | [8.5 d](/filings/0001628280-26-012013.md) | [(7.6)](/filings/0001628280-26-031742.md) | [0.1 d](/filings/0001628280-26-050836.md) | [19.5 d](/filings/0001628280-25-049902.md) | [12.8 d](/filings/0001628280-26-012013.md) | [15.1](/filings/0001628280-26-031742.md) | [14.3 d](/filings/0001628280-26-050836.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [153](/filings/0001628280-24-007824.md) | [164](/filings/0001628280-25-008447.md) | [198](/filings/0001628280-26-012013.md) | [237](/filings/0001628280-26-012013.md) | [276](/filings/0001628280-26-012013.md) |
| Gross margin | % | [69.3%](/filings/0001628280-24-007824.md) | [67.1%](/filings/0001628280-25-008447.md) | [68.6%](/filings/0001628280-26-012013.md) | [72.6%](/filings/0001628280-26-012013.md) | [74.4%](/filings/0001628280-26-012013.md) |
| Operating margin | % | [(5.1%)](/filings/0001628280-24-007824.md) | [(10.4%)](/filings/0001628280-25-008447.md) | [(3.3%)](/filings/0001628280-26-012013.md) | [1.9%](/filings/0001628280-26-012013.md) | [4.0%](/filings/0001628280-26-012013.md) |
| Net margin | % | [(4.9%)](/filings/0001628280-24-007824.md) | [(10.2%)](/filings/0001628280-25-008447.md) | [(1.6%)](/filings/0001628280-26-012013.md) | [4.4%](/filings/0001628280-26-012013.md) | [6.0%](/filings/0001628280-26-012013.md) |
| Diluted EPS | $ per share | [(0.16)](/filings/0001628280-24-007824.md) | [(0.35)](/filings/0001628280-25-008447.md) | [(0.07)](/filings/0001628280-26-012013.md) | [0.20](/filings/0001628280-26-012013.md) | [0.32](/filings/0001628280-26-012013.md) |
| Free cash flow | $m | [21.1](/filings/0001628280-24-007824.md) | [10.1](/filings/0001628280-25-008447.md) | [15.3](/filings/0001628280-26-012013.md) | [(5.8)](/filings/0001628280-26-012013.md) | [24.7](/filings/0001628280-26-012013.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vcel/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $360.0m | 8,092,226 |  | Added +326,882 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $146.6m | 3,293,975 |  | Added +141,845 |
| [CONGRESS ASSET MANAGEMENT CO](/funds/897378.md) | 2026-06-30 | $129.7m | 2,916,295 |  | Added +1,409,377 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $100.4m | 2,255,728 |  | Added +24,972 |
| [Conestoga Capital Advisors, LLC](/funds/1163744.md) | 2026-06-30 | $92.7m | 2,083,832 |  | Reduced −379,480 |
| [WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC](/funds/1644956.md) | 2026-06-30 | $88.7m | 1,992,855 |  | Added +160,146 |
| [BNP PARIBAS ASSET MANAGEMENT Holding S.A.](/funds/1520354.md) | 2026-06-30 | $73.0m | 1,639,988 |  | Reduced −83,584 |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $64.9m | 1,459,152 |  | Reduced −1,089,927 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $59.7m | 1,341,244 |  | Added +86,382 |
| [GENEVA CAPITAL MANAGEMENT LLC](/funds/1009232.md) | 2026-06-30 | $59.6m | 1,339,123 |  | Reduced −307,695 |

## Recent filings

[All 1,226 filings](/companies/vcel/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-30 | 08:49 ET | [10-Q](/filings/0001628280-26-050836.md) | Quarterly report, period 2026-06-30 | 0001628280-26-050836 |
| 2026-07-30 | 08:03 ET | [8-K](/filings/0001628280-26-050815.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-050815 |
| 2026-05-18 | 16:05 ET | [8-K](/filings/0001140361-26-021892.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001140361-26-021892 |
| 2026-05-07 | 08:54 ET | [10-Q](/filings/0001628280-26-031742.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031742 |
| 2026-05-07 | 07:57 ET | [8-K](/filings/0001628280-26-031713.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-031713 |
| 2026-05-01 | 16:05 ET | [8-K](/filings/0001140361-26-018538.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-26-018538 |
| 2026-03-19 | 07:30 ET | [DEF 14A](/filings/0001308179-26-000094.md) | Proxy statement, period 2026-04-29 | 0001308179-26-000094 |
| 2026-02-26 | 09:00 ET | [10-K](/filings/0001628280-26-012013.md) | Annual report, period 2025-12-31 | 0001628280-26-012013 |
| 2026-02-26 | 08:02 ET | [8-K](/filings/0001628280-26-012003.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-012003 |
| 2026-01-13 | 09:11 ET | [8-K](/filings/0001140361-26-001060.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-001060 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012013.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/54484d75-8236-42fc-b548-5262a7e75371)

## About the filer

- CIK: 887359
- Tickers: VCEL
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: MI
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.